Investment Rating - The report assigns an "Outperform" rating to several companies, including Pop Mart, Anta Sports, Huazhu Group, Li Ning, Miniso, and others, with target prices ranging from 6.99 to 354.00 [1]. Core Insights - The report highlights the enhanced subsidized interest policy for personal consumption loans, which has been extended until the end of 2026, including support for credit card installment payments and the removal of certain limits on subsidy amounts [2]. - Pop Mart's new PUCKY series has gained significant popularity, being referred to as the "electronic wooden fish" due to its unique design and emotional stress-relief features [3]. - Weekly performance shows TCL Electronics (+24.8%), Pop Mart (+23.0%), and others leading the market, while companies like Ecovacs (-1.2%) and Haier Smart Home (-2.2%) lag behind [5][9]. Company Summaries - **Pop Mart**: Recently launched the PUCKY series, which quickly sold out and is now being resold at a premium on secondary markets [3]. The company also repurchased 1.9 million shares [7]. - **TCL Electronics**: Established a joint venture with Sony to take over Sony's home entertainment business, reflecting strategic growth initiatives [8]. - **Huazhu Group**: Engaged in strategic partnerships and is expected to benefit from the ongoing trends in the hospitality sector [4]. - **Li Ning**: Continues to perform well in the market, maintaining a positive outlook with an "Outperform" rating [1]. Industry Dynamics - The report notes significant strategic partnerships, such as Saint Bella's collaboration with Yunji Technology to explore AI and robotics in home care [15]. - The IPO of Busy Ming was oversubscribed by over 1,500 times, indicating strong market interest [10]. - Regulatory developments include the State Council's solicitation of opinions on national standards for pre-made dishes, which could impact the food and beverage sector [10].

[Table_Title] 研究报告 Research Report 25 Jan 2026 中国策略 China Strategy 春节红包行情蓄力稳行，科技与价值各有亮点 Spring Festival "Red Packet" Rally Builds Momentum Steadily, with Highlights in Both Tech and Value 周林泓 Amber Zhou 黄雨昕 Yuxin Huang 从本周表现看，大盘如期震荡休整，市场整体情绪有所降温之后更健康，半导体走势偏强，航天军工等方向短期 震荡调整之后再次回暖。 我们判断，春节红包行情仍将蓄力稳行。从结构来看依然聚焦"高科技+强周期"，具体而言： ——高科技方向的机会：一方面，可继续延着当前年报预告业绩超预期的方向，深挖半导体特别是存储、储能、 电网设备、化工、创新药等方向。另一方面根据十五五规划相关的产业引领，进一步聚焦掘金国防军工、国产算 力/芯片、太空算力、可控核聚变等领域龙头。 ——价值方向的机会：首先，继续持有黄金及相关权益资产。其次，在震荡中择机布局性价比高、基本面改善的 低位价值股机会，关注港股具有业绩 ...

Investment Rating - The report does not explicitly state an investment rating for the semiconductor industry or Intel, but it highlights strong performance metrics that suggest a positive outlook for the company. Core Insights - Intel delivered a solid fourth quarter for 2025, with revenue reaching $13.7 billion, surpassing both its guidance and consensus estimates, driven by growth in AI infrastructure and server segments [1][8] - The company achieved a non-GAAP gross margin of 37.9%, exceeding guidance by approximately 140 basis points, and a non-GAAP EPS of $0.15, significantly outperforming expectations [1][8] - Intel anticipates a CPU supply shortage in 1Q26 due to depleted buffer inventories, with improvements expected starting in 2Q26 as production efficiency increases [3][11] - The foundry business is progressing, with Intel beginning shipments of its 18A process and reporting steady yield improvements [4][12] Summary by Sections Financial Performance - In 4Q25, Intel's revenue was $13.7 billion, exceeding guidance and consensus estimates, with a non-GAAP gross margin of 37.9% and a non-GAAP EPS of $0.15 [1][8] - For 1Q26, Intel forecasts revenue between $11.7 billion and $12.7 billion, with a midpoint of $12.2 billion, lower than consensus due to supply constraints [5][13] Capital Expenditure (CapEx) - CapEx for 2026 is expected to be flat or slightly down due to balancing capital efficiency with demand signals, but a significant yield improvement of 7% to 8% has been reported [2][10] - Intel is securing equipment from suppliers like ASML to mitigate lead time issues, with an expected increase in CapEx in 2027 to support manufacturing expansion [2][10] Supply Chain and Production - Intel identifies 1Q26 as a critical period for CPU supply shortages, primarily due to production shifts towards server wafers [3][11] - The company is experiencing significant demand for CPUs driven by AI workloads, which is expected to sustain shortages for several years [3][11] Foundry Business Development - Intel's foundry revenue reached $4.5 billion, with successful shipments of the 18A process and steady yield improvements [4][12] - Development of the 14A process is on track, with customer engagement expected to lead to firm supply decisions in late 2026 to early 2027 [4][12]

Investment Rating - The report maintains an "Outperform" rating for ANTA Sports [2][5] Core Insights - ANTA Brand experienced its first low-single-digit negative sell-through growth in 4Q25 after 11 consecutive quarters of positive growth, primarily due to offline sales decline and challenges in the children's category, although it still achieved a full-year low-single-digit growth target [3][10] - FILA Brand achieved mid-single-digit sell-through growth in both 4Q25 and for the full year 2025, with increased discounts and a stock-to-sales ratio slightly above 5x [3][10] - Management is cautious about 2026, planning increased investments in brand and marketing due to significant sporting events such as the Milan Winter Olympics, World Cup, and Asian Games [3][10] Financial Summary - Revenue projections for ANTA Sports from 2025 to 2027 are RMB 78.26 billion, RMB 85.00 billion, and RMB 92.04 billion, representing year-on-year growth of 10.5%, 8.6%, and 8.3% respectively [5][12] - Net profit attributable to parent shareholders is expected to be RMB 12.98 billion, RMB 14.34 billion, and RMB 16.24 billion for the same years, with year-on-year changes of -13.1%, 14.6%, and 13.8% respectively [5][12] - The corresponding P/E ratios for 2025 to 2027 are projected at 16.0x, 14.5x, and 12.8x [5][12]

Market Performance - Southeast Asia ETF rose by 2.93% over the two-week period from January 3, 2026, to January 16, 2026, outperforming China, the UK, the US, and India, but underperforming Japan, Latin America, and Africa[2] - The Southeast Asia Technology ETF increased by 1.51%, lagging behind the broader Southeast Asia ETF by 1.42 percentage points[2] Country-Specific Performance - iShares MSCI Indonesia ETF increased by 2.18%, underperforming the Southeast Asia ETF by 0.75 percentage points, supported by positive growth forecasts and economic recovery data[3] - iShares MSCI Singapore ETF rose by 1.08%, underperforming by 1.85 percentage points, with strong trading data and optimistic economic outlooks providing support[3] - iShares MSCI Thailand ETF gained 0.67%, underperforming by 2.26 percentage points, influenced by expectations of interest rate cuts and weak economic growth prospects[3] - iShares MSCI Malaysia ETF increased by 3.14%, outperforming by 0.20 percentage points, driven by a decline in unemployment to a multi-year low and targeted government financial support measures[3] - Global X MSCI Vietnam ETF edged up by 0.08%, underperforming by 2.85 percentage points, with stable performance supported by strong trade fundamentals[3] Trading Volume and Liquidity - The trading volume for Global X FTSE Southeast Asia ETF reached 529,000 shares, a week-on-week increase of 87.3%[14] - iShares MSCI Singapore ETF saw a trading volume of 8.583 million shares, up by 49.3% week-on-week[14] - iShares MSCI Indonesia ETF trading volume was 4.445 million shares, increasing by 119.8% week-on-week[14] Economic Indicators - Malaysia's unemployment rate fell to 2.9%, the lowest in 11 years, indicating a resilient job market[22] - Indonesia's GDP growth for Q4 2025 was reported at 5.45%, marking a recovery trend[16]

Investment Rating - The report initiates coverage with an OUTPERFORM rating, setting a target price of ₩22,000, while the current price is ₩17,970 [2]. Core Insights - Hite Jinro's strong market position in the soju segment, with nearly 70% market share, provides a solid foundation for stable cash flow and profit growth, even amidst industry challenges [4][7]. - The company is expected to implement a 5% price increase in the soju segment in Q2 2026, which, combined with economies of scale, could push operating profit margins (OPM) closer to 13% [4]. - The overseas expansion strategy, particularly with the upcoming Vietnam factory and entry into the Indian market, is anticipated to drive significant revenue growth, overcoming domestic market saturation [5][30][33]. - The report highlights the defensive characteristics of the essential consumer sector, suggesting that Hite Jinro could attract new capital as the market seeks balanced valuations [6]. Summary by Sections Company Overview - Hite Jinro's revenue structure is heavily reliant on soju, contributing approximately 58% of total revenue, while beer contributes about 32% [27]. - The company has a strong brand presence, with "Chamisul" and "Chamisul" accounting for over 90% of soju revenue [29]. Financial Performance - Revenue projections for 2025-2027 are estimated at ₩25,960 billion, ₩26,580 billion, and ₩27,340 billion, with net profits of ₩1,060 billion, ₩1,230 billion, and ₩1,290 billion respectively [41]. - The report anticipates a stable operating profit margin for soju at 12-13%, while beer margins are expected to remain under pressure at 2.5-3% [36][37]. Market Dynamics - The Korean alcohol market is characterized by a unique dominance of soju, which accounts for 42% of the market, contrasting with global trends where beer typically holds a larger share [8]. - The beer market is facing challenges, with a projected decline in sales due to consumer preference shifts towards lower-priced products [14][15]. Strategic Initiatives - The establishment of a production facility in Vietnam is expected to enhance competitiveness in Southeast Asia by reducing supply costs and avoiding import tariffs [32]. - The entry into the Indian market represents a significant growth opportunity, despite regulatory challenges and the need for consumer education [33].

Investment Rating - The report gives the company an "Outperform" rating with a target price of 118.57 HKD, corresponding to a 2025 PE of 26x and a reasonable valuation of 149 billion RMB (approximately 166 billion HKD) [1][7]. Core Insights - The company has been deeply engaged in the oil-based skincare sector for many years, leveraging platforms like Douyin to drive the explosive growth of its flagship products. The expansion of product categories and channels is expected to lead to sustained rapid growth [1][7]. - The company has established itself as a leader in the oil-based skincare market, with a significant market share in facial essence oils, projected to reach 12.4% in 2024, significantly ahead of competitors [3][37]. - The financial forecasts indicate substantial revenue growth, with total revenue expected to reach 23.16 billion RMB in 2025, representing a year-on-year increase of 91.5% [2][12]. Company Overview - The company, Lin Qingxuan, was founded in 2003 and has evolved from offering handmade soaps and aloe vera gels to becoming a pioneer in oil-based skincare with its flagship product, Camellia Oil Essence, launched in 2014 [3][17]. - The management team is experienced and stable, with the founder holding over 70% of the shares, ensuring concentrated ownership and strategic direction [22][26]. Business Performance - The flagship product, the Camellia Oil Essence, has seen rapid growth, with revenue from this category increasing by 176% year-on-year in the first half of 2025, accounting for 46% of total revenue [3][28]. - Online sales have surged, with Douyin driving a 137% increase in online revenue in the first half of 2025, contributing to a 65% share of total revenue [3][36]. Industry Insights - The oil-based skincare segment is experiencing high demand, with the market for facial essence oils projected to grow to 5.3 billion RMB in 2024, reflecting a year-on-year increase of 43% [3][37]. - The overall anti-aging skincare market is expected to reach 119.9 billion RMB in 2024, with a significant portion attributed to high-end products [37][39].

US Macro - The CPI rose by 0.3% in December, meeting expectations, with a year-on-year increase of 2.7%, unchanged from November. The core CPI increased by 2.6%, slightly below the expected 2.7% [6][28] - The overall CPI increase was primarily driven by food prices, which rose by 0.7% in December, marking the largest increase since 2022. Energy prices also saw a slight increase, but gasoline and fuel prices declined [6][8] - The US is likely at the forefront of low inflation globally, with core inflation remaining below the Fed's 2% target for the second consecutive month and lower than the average in most developed markets [7][35] - Tariff-related core goods inflation has shown a clear cooling trend since peaking in September 2025, indicating that the impact of tariffs on inflation has passed its peak and continues to be lower than expected [7][35] - Service inflation remains dominant, with housing prices rising by 0.4% in December, the largest increase since August 2025, contributing significantly to the overall CPI [8][35] CPI and PCE Differences - The Federal Reserve's long-term inflation target is set at 2% annual growth in PCE, making it the primary benchmark for monetary policy, while CPI is more commonly referenced in short-term market reactions [30][18] - PCE has broader coverage than CPI, including government and employer-paid healthcare, which is not reflected in CPI, aligning better with GDP accounting [30][18] - The market typically focuses more on CPI due to its earlier release and historical familiarity, while the Fed uses PCE for long-term trends [21][30]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The report maintains a "Neutral" rating for Monster Beverage Corp (MNST US) with a current price of $77.91 and a target price of $71.64 [2][5]. Core Insights - The company is set to launch its largest innovation pipeline in 2026, which includes new product lines targeting women, juice and functional beverages, and multiple zero-sugar products [3][12]. - International revenue and profit contributions have reached record highs, with international revenue growing 23% year-over-year in Q3 2025, now accounting for 43% of total revenue [4][13]. - A new pricing strategy implemented in the U.S. market is expected to enhance profit margins with limited negative impact on sales volume [14]. Financial Performance Summary - Revenue projections for 2025-2027 are $8.16 billion, $8.75 billion, and $9.45 billion, respectively, with growth rates of 9%, 7%, and 8% [2][10]. - Net profit is forecasted to be $2.11 billion, $2.34 billion, and $2.56 billion for the same period, reflecting growth rates of 15.6%, 10.9%, and 9.3% [5][15]. - The diluted EPS is expected to increase from $2.14 in 2025 to $2.63 in 2027 [2][10]. Market Expansion Strategy - The company is enhancing its distribution partnership with Coca-Cola to penetrate new channels such as foodservice and universities, particularly in EMEA, Asia-Pacific, and Latin America [4][13]. - The affordable energy drink line, represented by brands like Predator and Fury, is targeting lower-income markets and has expanded to 36 markets [4][13].